TNFAIP3 and arthritic joint disease: Takinib is a potent (9 nM) and highly selective inhibitor of TAK1 [365] that exhibits activity in arthritis models [366] and in a Hodgkin's Lymphoma model with mutation of the A20 DUB [367].